Catheter Precision, Inc. (NYSE: VTAK)

Catheter Precision Inc is a medical technology company focused on the design, manufacture, and sale of innovative products for cardiac electrophysiology procedures. The company’s primary offerings include the VIVO System, a non-invasive imaging tool for 3D cardiac mapping to localize ventricular arrhythmia origins, and LockeT, a suture retention device for wound healing and efficient suture management. Catheter Precision Inc operates within the healthcare sector, specifically serving the electrophysiology market which addresses diagnosis and treatment of heart rhythm disorders.

Catheter Precision Inc generates revenue through the sale of its VIVO System and LockeT products to hospitals and electrophysiology labs. The VIVO System requires disposable VIVO Positioning Patches for each procedure, creating a recurring revenue stream. LockeT is sold as a sterile, single-use device. The company also sells the Amigo Remote Catheter System, a robotic arm for catheter control, though this product is currently under evaluation for future development and not a primary revenue driver. Sales occur both domestically through direct sales teams and internationally via distributors.

The company operates through the following segments:

• VIVO System segment includes the non-invasive 3D cardiac mapping system, associated software, disposable Positioning Patches, and related clinical support activities used to localize ventricular arrhythmia origins prior to ablation procedures.

• LockeT segment includes the suture retention device indicated for wound healing by distributing suture tension, securing sutures, and aiding in their efficient location and removal during vascular access procedures.

• Amigo segment includes the Remote Catheter System, a robotic arm device for catheter control, which is owned by the company and under consideration for future research and development of a second-generation product.

Catheter Precision Inc holds a niche position in the competitive electrophysiology market dominated by large medical device companies such as Medtronic Plc Abbott Laboratories Biosense Webster (a division of Johnson & Johnson) and Boston Scientific Corp. The company differentiates itself through its non-invasive VIVO System which reduces procedure time and anesthesia exposure by enabling pre-procedural localization of arrhythmia sites. LockeT offers advantages over traditional vascular closure devices by improving hemostasis reducing time to ambulation and lowering procedural costs. The company’s focus on underserved ventricular arrhythmia treatment and its portfolio of FDA-cleared and CE-marked products support its competitive standing.

Catheter Precision Inc serves hospitals and electrophysiology labs performing cardiac ablation procedures. The company’s primary customers are healthcare institutions providing ventricular and atrial fibrillation treatments. During fiscal 2025 two individual customers represented approximately 28% and 12% of total revenues respectively with three customers collectively accounting for about 50% of revenue. The company estimates there are 2,000 to 3,000 electrophysiology labs in the U. S. and a similar number internationally performing approximately 600,000 ablation procedures annually.